An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer

BACKGROUND: Apalutamide, a nonsteroidal potent androgen receptor antagonist, was safe and effective in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic-CRPC (mCRPC) in global studies. In this phase 1 study, safety, pharmacokinetics (PK), and efficacy of apalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchiya, Tomohiro, Imanaka, Keiichiro, Iwaki, Yuki, Oyama, Ryo, Hashine, Katsuyoshi, Yamaguchi, Akito, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861345/
https://www.ncbi.nlm.nih.gov/pubmed/31446511
http://dx.doi.org/10.1007/s10147-019-01526-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861345/
https://www.ncbi.nlm.nih.gov/pubmed/31446511
http://dx.doi.org/10.1007/s10147-019-01526-7

Ejemplares similares